NCTR Research Highlights | Adapting Genetic Toxicology Endpoints To In Vitro Tissue Models

Read about NCTR's latest research highlight.

If your email program has trouble displaying this email, view as a webpage. You are subscribed to the National Center for Toxicological Research (NCTR) Research Highlights for the U.S. Food & Drug Administration (FDA). This content has been updated.   Adapting Next-Generation Genetic Toxicology Endpoints to In Vitro Human Organotypic Tissue Models Organotypic in vitro tissue models are expected to create unique opportunities to improve predictive toxicology, reduce animal testing, and advance regulatory science. More   *Note:  Please feel free to share this email with others. Received this email from a friend or colleague? Subscribe here.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA